Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | August 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E

Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | August 2022

2 Certain information in this presentation may include forward-looking statements (including within

the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters.

These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as assumptions made

by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will,"

"should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast," "guidance", "outlook" and other similar expressions. Forward-looking statements are based on current beliefs and assumptions

that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without

limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations regarding its plans for

future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict

the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it difficult to evaluate

the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203

and other Versamune and Infectimune based product candidates; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration studies

concerning PDS0101, PDS0203 and other Versamune and Infectimune based product candidates and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the

future success of the Company's product candidates; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing

of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund its disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses,

presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the

Company's ongoing clinical trials; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, PDS0101, PDS0203 and other

Versamune and Infectimune based product candidates; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development

programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or other disruptions to normal business

operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that

are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required

by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune is a

registered trademark, and Infectimune is a trademark of PDS Biotechnology Corporation.KEYTRUDA is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Forward-Looking Statements 2

1 2 4 5 6 Company Overview Clinical-stage Company developing targeted immunotherapies to treat

cancer and infectious disease Versamune and Infectimune platforms leverage the body's own defense systems to induce disease-specific killer T cells and antibodies to combat cancer and infectious disease Versamune has demonstrated

potential to overcome immune suppression in refractory cancer with prolonged patient survival Clinical partnerships with Merck, MD Anderson Cancer Center, National Cancer Institute and Mayo Clinic Debt free with approximately $53.0M in cash

(unaudited) as of June 30, 2022 - projected to fund operations into 2024 3 Technology developed by Prof. Leaf Huang PH.D., a world-renowned pioneer in nanoparticle drug delivery 3 Lead candidate - PDS0101 granted Fast Track designation

Versamune Oncology Platform

Generate memory T cells, to enhance durability of response Generate potency without serious systemic

side effects Generate the right type and quantity of effective CD8+ killer T cells 12-30% Success in checkpoint inhibitor treatments due to low CD8+ T-cell response 2 Versamune is designed to promote CD8+ killer T-cell responses in

vivo The PDS Biotech Differentiation Versamune based therapies also show promising potential to1: 1Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine, Journal for ImmunoTherapy of Cancer, June 2020 5 2 Bintrafusp

alfa, a bifunctional functional fusion protein targeting TGF- and PD-L1, in patients with human papillomavirus-associated malignancies Journal for ImmunoTherapy of Cancer, December 2020

References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid

nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Smalley R umfield C et al. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.

J. for ImmunoTherapy of Cancer 8:e000612. Versamune Platform Designed to Recruit, Train and Arm T cells in the Body 6

Combination PDS Biotech Funded Partner Co-Funded Versamune Platform Versamune based oncology

pipeline is being developed in partnership with the leaders in immuno oncology PDS0104 (TRP2) TBD Arm 1: CPI na ve 1st line treatment Arm 2: CPI refractory 2nd or 3rd line treatment PDS0101 (HPV16) VERSATILE-002 Fast Track

Designation PDS0101 (HPV16) IMMUNOCERV PDS0102 (TARP) PDS0103 (MUC1) Candidate Indication PC P1 P2 P3 R Partner(s) Recurrent/metastatic HPV16-positive head and neck cancer KEYTRUDA (standard of care) HPV-positive anal,

cervical, head and neck, penile, vaginal, vulvar cancers Arm 1: CPI naive 2nd line treatment Arm 2: CPI refractory 3rd line treatment Bintrafusp and M9241 1st line treatment of locally advanced (IB3-IVA) cervical cancer TARP-associated

AML, prostate and breast cancers MUC-1 associated breast, colon, lung, ovarian and other cancers Chemo-radiation (standard of care) TBD TBD Reference: Data on file. 7 PDS0101 (HPV16) Mayo Clinic Pre-metastatic HPV-associated

oropharyngeal cancer (OPSCC) Arm 1: PDS0101 monotherapy Arm 2: PDS0101 + KEYTRUDA KEYTRUDA (standard of care) PDS0101 (HPV16) NCI-led Triple Combination Melanoma

More than 46,0002 patients were estimated to have been diagnosed last year with HPV-associated cancers

in the US1,2 HPV vaccination is not expected to impact the rate of HPV-related cancer incidence for decades3 Existing immunotherapies cost $150,000+ annually per patient1 US HPV-associated cancer incidence2 1Company estimates based on CDC

data. Assessments have not been adjusted to reflect HPV16-expression 2CDC website 3 Projected Association of Human Papillomavirus Vaccination with Oropharynx Cancer in the US 2020-2045, JAMA Oncology, September 2021 PDS0101: Lead

Asset Designed to treat human papillomavirus (HPV16)-associated cancers $6B Market Opportunity1 Reference: Data on file. 8

Phase 2: PDS0101 in Combination with KEYTRUDA Company-sponsored trial for the treatment of

HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Status Fast Track designation Q2 2022 Efficacy and safety data presented on first 19 patients at ASCO Q2 2022 Data safety monitoring committee reviewed 43 patients;

recommends trial continuation Q2 2022 Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA (Standard of Care): Anti-PD1 checkpoint inhibitor (ORR

~20%) PDS0101: Versamune based immunotherapy generating HPV-specific CD8+ and CD4+ T cells Study Goals Group 1: Objective response rate (ORR) as 1st line treatment in checkpoint inhibitor (CPI) na ve patients Group 2: ORR in patients who

have failed checkpoint inhibitor therapy (CPI refractory) Trial Partner Confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand evaluation of Versamune -based therapies in multiple cancer

Phase 2: PDS0101 + KEYTRUDA Company-sponsored trial for the treatment of HPV16-positive

metastatic/recurrent head and neck cancer (VERSATILE-002) 10 Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive Disease (PD) N=17 Subjects w/Imaging Data OR (2 CR + 5PR) 7 (41.2%) SD (reduction in 4/6) 6

(35.3%) PD 4 (23.5%) CR+PR+SD 13 (76.5%) *Reference: Weiss J. et al. Phase II study VERSATILE-002 evaluation of PDS0101 and KEYTRUDA in treatment of CPI na ve and CPI refractory patients with recurrent or metastatic HPV16-related HNSCC.

Presented at: American Society of Clinical Oncology 2022 Annual Meeting; June 3-7, 2022; Virtual. Abstract: 6041.

Phase 2: PDS0101 + KEYTRUDA Company-sponsored trial for the treatment of HPV16-positive

metastatic/recurrent head and neck cancer (VERSATILE-002) 11 Treatment Emergent Adverse Events (TEAEs) Safety Population (N=19) CPI Na ve Subjects (N=19) N (%) : Events Subjects with any TEAEs Grade 1 Grade 2 Grade 3 Grade 4 Grade

5 18 (94.7%) : 371 3 (15.8%) : 3038 (42,1%) : 51 5 (26.3%) : 110 (0.0%) : 4 2 (10.5%) : 2 Grade 3 TEAEs Attributed to Study Treatment by Investigator No subjects met this criteria 0 Grade 3 & 4 Treatment Related TEAEs No

subjects met this criteria 0 At 9 Months of Follow Up (Median PFS not yet Achieved) % of Patients Alive at Median 9 Months 89% Progression Free Survival Rate (PSF) 55.2% Overall Survival Rate (OS) 87.2% *Reference: Weiss J. et al.

Phase II study VERSATILE-002 evaluation of PDS0101 and KEYTRUDA in treatment of CPI na ve and CPI refractory patients with recurrent or metastatic HPV16-related HNSCC. Presented at: American Society of Clinical Oncology 2022 Annual Meeting;

June 3-7, 2022; Virtual. Abstract: 6041.

Phase 2: PDS0101 + Bintrafusp alfa + M9241 (Triple Combination) NCI-led trial for the treatment of

HPV16-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers Status Updated efficacy and safety data released at ASCO Q2 2022 Preliminary efficacy and safety data released at ASCO Q2 2021 Indication Treatment of

patients with advanced refractory HPV16-associated cancers Clinical Agents Bintrafusp alfa: Bifunctional checkpoint inhibitor (PD-L1/ TGF- ) M9241 (NHS-IL12): Tumor-targeting IL-12 (immunocytokine) PDS0101: Versamune based immunotherapy

generating HPV-specific CD8+ and CD4+ T cells Study Goals Group 1: Objective response rate (ORR) as 2nd line treatment in checkpoint inhibitor (CPI) na ve patients Group 2: ORR in patients who have failed CPI therapy (CPI

refractory) Trial Partner Confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand evaluation of Versamune -based therapies in multiple cancer indications 12

PDS0101 Designed to Promote Efficacy in HPV16 Cancers Studies show key contributions of PDS0101, M9241

& Bintrafusp alfa* to clinical response to date 13 *Bintrafusp alfa monotherapy showed 30% ORR in CPI na ve and 10% ORR in CPI refractory HPV-positive cancers (Strauss et al, 2020, Dec 8(2) **All HPV16 negative and 80% of HPV16

positive patients had high dose M9241 Tumor reduction only seen in HPV16-positive patients P<0.001 High dose M9241 provides superior ORR vs. low dose P<0.01 Reference: Strauss J. et al. Phase II evaluation of the triple combination

of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2022 Annual Meeting; June 3-7, 2022; Virtual. Abstract: 2518.

Best Overall Response Active Against Diverse HPV16 Cancers PDS0101: Triple Combination Active

Against HPV16 Cancer Responses to date across tumor types and higher NHS-IL12 dose show the potential to result in greater clinical efficacy 14 *HNSCC - head and neck squamous cell carcinomas Higher M9241

Dose Cervical Vaginal/Vulvar Anal HNSCC* Percentage Change Weeks Baseline Responses Occurred Irrespective of Tumor Type Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa

in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2022 Annual Meeting; June 3-7, 2022; Virtual. Abstract: 2518. Best Overall Response is defined by RECIST 1.1

Phase 2: Triple Combination May Extend Patient Survival High dose M9241 may provide improved synergy

with PDS0101 15 CPI Na ve Subjects CPI Refractory Subjects Objective Response Rate (ORR) > 30% tumor shrinkage High Dose M9241 - 83% Low Dose M9241 (2/2) - 100% Overall - 88% High Dose M9241 - 63% Low Dose M9241 - 7% Overall -

27% Tumor shrinkage 88% High Dose M9241 - 63% Low Dose M9241 - 36% Overall - 45% Patient survival at median 12 months NA High Dose - 77% Low Dose - 77% Patient survival at median 17 months 75% NA Reference: Strauss J. et al.

Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2022 Annual Meeting; June 3-7, 2022; Virtual. Abstract:

Versamune + M9241 May Overcome CPI-Independent Tumor T Cell Evading Mechanisms Potential to advance

cancer immunotherapy 16 Tumors blocking T cell attack using immune checkpoints Tumors blocking T cell attack using alternative immune suppressive mechanisms KEYTRUDA unlocks checkpoint-dependent immune suppressive mechanism - PDS0101

primes T cells to attack and kill the cancers Tumors blocking T cell attack using immune checkpoints Tumors blocking T cell attack using alternative immune suppressive mechanisms Versamune + M9241 may unlock checkpoint-independent

immune suppressive mechanisms* and M9241 may induce tumor inflammation - PDS0101 primes T cells to attack and kill the cancers exposed by both CPI and Versamune + M9241 PDS0101 + KEYTRUDA PDS0101 + M9241 + Bintrafusp alfa (41% ORR) (88%

ORR) *Johnson K. et al; PDS Biotech US Patent #10,828,364

Phase 2: PDS0101 + Chemoradiotherapy Investigator-led trial evaluating the combination in patients

with locally advanced cervical cancer (IMMUNOCERV) Timing Preliminary data anticipated in Q4 2022 Indication Treatment of patients with locally advanced cervical cancer-Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT -Standard of

Care): Cisplatin and radiation therapy PDS0101: Versamune based immunotherapy generating HPV-specific CD8+ and CD4+ T cells Study Goals Safety, rate of regression and local control in patients with primary tumor 5cm (n=35

patients) Trial Partner If successful, this study could support further investigation of Versamune based immunotherapies in combination with chemotherapy or CRT to treat multiple cancers 3 17

KEYTRUDA : Cisplatin and radiation therapy PDS0101: Versamune based immunotherapy generating

HPV-specific CD8+ and CD4+ T cells 3 Phase 2: PDS0101 Monotherapy and in Comb. with KEYTRUDA Investigator-led trial evaluating treatments in patients with HPV-associated oropharyngeal cancer with high risk of

recurrence Timing Enrollment ongoing Indication Treatment of patients with oropharyngeal cancer prior to transoral robotic surgery Clinical Agents Study Goals Safety, rate of regression and local control in patients transoral robotic

surgery Trial Partner If successful, this study could support the expansion of PDS0101 to earlier stage disease 18

CFA + TARP (1-20) X PDS0102: TARP Antigen Versamune induced CD8+ killer T cells may result in the

ability to treat TARP positive AML and prostate cancers Pre-Clinical Optimization Studies1: TARP-Specific T-cell Induction after 2 injections of PDS0102 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8) CFA -Complete Freund's

Adjuvant a highly potent immune activator not used in humans due to potentially lethal toxicity *Reference: Surveillance Research Program, National Cancer Institute SEER Assumes $150K for annual course of therapy; in line with current

immunotherapy treatment.Assessments have not been adjusted to reflect TARP expression, which is currently unknown by tumor type $40B TARP Total Market Opportunity* Announced license with NCI TARP antigens Number of TARP-Specific T

cells (Interfer on-y spot forming cells per million splenocytes) 0 100 200 300 400 500 600 700 800 900 1000 100 spots/million cells Strong T-cell response level Range of observed T-cell responses with PDS0102 IFN-y ELISPOT

Study Versamune + TARP (1-20) X 3 19

Induced a >10-fold number of polyfunctional (highly potent) MUC1 specific CD8+ T cells PDS0103:

MUC1 Antigen Greater quantity and quality of Versamune induced CD8+ killer T cells may result in the ability to treat breast, ovarian, lung, and colon cancers *References: Surveillance Research Program, National Cancer Institute SEER,

Cancer Institute SEER, Assumes $150K for annual course of therapy; in line with current immunotherapy treatment, Assessments have not been adjusted to reflect MUC1-expression, which is currently unknown by tumor type Adjuvant = cytokine

GMCSF J. Immunology, 2019 (202),1215; Studies in TC-1 tumor model with other immunotherapies reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27